Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma (IMRT)
Nasopharyngeal Carcinoma
About this trial
This is an interventional treatment trial for Nasopharyngeal Carcinoma focused on measuring concurrent chemotherapy, IMRT, recurrent NPC
Eligibility Criteria
Inclusion Criteria:
1.Pathologically or clinically confirmed rT3/T4 locally recurrent nasopharyngeal carcinoma;
2.No evidence of distant metastasis
3.More than 1 year from the end of the first course of radiotherapy
4.Male, or female not in the phase of lactating or pregnancy
5.ECOG 0-2
6.Aged 18-70 years old
7.WBC count ≥4×109/L, neutrophile granulocyte count≥1.5×109/L, PLT count ≥100×109/L, Hb ≥9g/L
8.Total bilirubin, AST, ALT≤2.0 times of upper normal limits; creatinine ≤1.5 times of upper normal limits
9.Written informed consort signed
Exclusion Criteria:
- Only regionally recurrence
- Evidence of distant metastasis
- Prior invasive malignancy; noninvasive cancers (For example, carcinoma in situ of the bladder, oral cavity, or cervix are all permissible) are permitted
- Severe, active co-morbidity
- Prior anti-tumor treatment after diagnosis of local recurrence
- MRI was not performed 3 months after the first course of radiotherapy
- Abnormal function of heart, brain and lungs, etc
- Lactation or pregnancy
- Severe nasopharyngeal mucosal necrosis at the diagnosis of local recurrence
Sites / Locations
- WangHanYuRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
IMRT and concurrent cisplatin
IMRT alone
IMRT and concurrent cisplatin to treat T3/T4 locally recurrent NPC patients. Cisplatin 100mg/M2 is to give D1,D22 of IMRT for 2 cycles. IMRT is to give GTV 60Gy in 27 fraction
IMRT alone to treat T3/T4 locally recurrent NPC patients. IMRT is to give 60Gy in 27 fraction